GSK declares second PhIII win for Blenrep combo in bid to revive drug

Blenrep, GSK’s BC­MA-tar­get­ing an­ti­body-drug con­ju­gate, has once again beat the stan­dard of care when giv­en as part of a com­bi­na­tion to pa­tients with re­lapsed/re­frac­to­ry mul­ti­ple myelo­ma who have re­ceived at least one treat­ment, the British drug­mak­er said.

GSK has been build­ing its case for bring­ing the can­cer drug back to mar­ket af­ter yank­ing it from the US in 2022 on dis­ap­point­ing con­fir­ma­to­ry da­ta. Blenrep had been grant­ed an ac­cel­er­at­ed ap­proval in 2020 as a monother­a­py but failed to im­prove pro­gres­sion-free sur­vival (PFS) over the PomDex reg­i­men, which com­pris­es po­ma­lido­mide and low-dose dex­am­etha­sone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.